Clinical trials
Gastric clinical trials
Below are recruiting gastric clinical trials, each written for real people, not researchers. We’re tracking 849 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06293703Recruiting
Leg length ratio and weight loss after gastric bypass
This study looks at how the length of different parts of your small intestine affects weight loss after Roux-en-Y gastric bypass surgery. It may help doctors tailor the surgery for better results.
Cleveland, OhioAges 18–70 - NCT06289374Recruiting
Long-term breath & blood study after stomach or esophagus cancer surgery
This study is for people who have had surgery for stomach or esophagus adenocarcinoma and are already part of a larger study called BIORESOURCE 1. It looks at certain substances in your breath and blood over time to learn more about recovery.
LondonAges 18–90 - NCT06277024Recruiting
Combination therapy for advanced HER2-negative stomach cancer
This trial tests a combination of immunotherapy (candenizumab), a targeted therapy (lenvatinib), and chemotherapy (SOX regimen) for advanced HER2-negative stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatments.
Fuzhou, FujianAges 18–75 - NCT06275204Recruiting
H. pylori test and treat study for young adults
This study tests and treats young adults for H. pylori, a stomach bacteria, to see if treating it reduces future health risks. If you haven't been treated for H. pylori before, you may join.
Zagreb, City of ZagrebAges 30–34 - NCT05762991Recruiting
AI test to help diagnose stomach bacteria and early stomach changes
This trial checks whether an artificial intelligence (computer) system can help diagnose Helicobacter pylori (a common stomach bacteria) and early stomach “premalignant” changes using endoscopy results. It may help doctors spot problems more accurately when you have a scheduled scope.
TaipeiAges 20–80 - NCT06253871RecruitingPhase 1
Study of IAM1363 for HER2 Cancers
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
La Jolla, CaliforniaAges 18 years+ - NCT06266299RecruitingPhase 1
Study of KK2269 for adults with solid tumors
This trial tests a new drug called KK2269 for adults with solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, possibly as a treatment option for certain cancers like lung or stomach cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06228963RecruitingPhase 2
Orelabrutinib for H. pylori-positive gastric MALT lymphoma
This trial tests a targeted drug called orelabrutinib for people with a specific type of stomach lymphoma that is linked to an active H. pylori infection. The goal is to see if the drug can help shrink or control the lymphoma.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06222645Recruiting
Comparing two dyes in gastrointestinal surgery
This trial compares two dyes used during stomach or intestine surgery to see which helps surgeons see the blood flow better. It may help decide which dye works best for safe reconnections.
Yantai, ShandongAges 18 years+ - NCT06227728Recruiting
Predicting immunotherapy response in advanced cancer
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
Ho Chi Minh City, Hồ Chí MinhAges 18–80 - NCT06219941RecruitingPhase 2
Studying AZD0901 for Claudin18.2-positive advanced solid tumors
This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.
Orange, CaliforniaAges 18 years+ - NCT07671625Recruiting
Prehabilitation program for esophageal or gastric cancer
This trial tests a comprehensive program that includes exercise, nutrition, and psychological support before and after surgery for patients with locally advanced esophageal or gastric cancer. It aims to improve recovery and outcomes.
BrnoAges 18 years+ - NCT02012699Recruiting
Cancer registry for people with or at risk of cancer
This trial collects health information and samples (a “cancer repository”) to help researchers study cancer and cancer risk. You may be able to join if you’ve had cancer before or if you’re at higher risk or have concerning findings.
Greenwood Village, ColoradoAges 19–110 - NCT05777512Recruiting
Comparing feeding tube placement to improve breathing in preterm infants
This study tests whether placing a feeding tube past the stomach (postpyloric) can help very premature babies with ongoing lung problems breathe better. Infants born before 32 weeks who still need breathing support may join.
Boston, MassachusettsAges birth–1 year - NCT06203327Recruiting
Can atrophic gastritis predict stomach cancer risk?
This trial studies whether a condition called atrophic gastritis (thinning of the stomach lining) can help predict who is more likely to develop stomach cancer. It may help with early detection and prevention.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT06196697RecruitingPhase 2
New immunotherapy combo for advanced stomach cancer
This clinical trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus chemotherapy as the first treatment for advanced stomach or gastroesophageal junction cancer. It aims to see if this combination helps control the cancer better than standard therapy.
HarbinAges 18–75 - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06163729RecruitingPhase 2
Testing camrelizumab plus chemo and radiation before/after surgery for stomach-esophagus cancer
This trial tests combining the immunotherapy drug camrelizumab with chemotherapy and radiation before and after surgery for a specific type of stomach-esophagus cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18–80 - NCT06157996RecruitingPhase 2
Lenvatinib, Tislelizumab, and CapeOX for advanced stomach cancer
This trial tests a combination of three drugs (lenvatinib, tislelizumab, and CapeOX chemotherapy) as the first treatment for advanced stomach or gastroesophageal junction cancer that is PD-L1 positive and has a low TMEscore. The goal is to see if this combination helps control the cancer better than standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT06158919Recruiting
Immunotherapy Plus Targeted Therapy and Chemo for Stomach Cancer
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06134960RecruitingPhase 1
KD-496 CAR T-cells for advanced solid tumors with NKG2DL or CLDN18.2
This trial tests a new type of immune cell therapy called KD-496, which is a CAR T-cell designed to attack tumors that have NKG2DL or CLDN18.2 markers. It may be an option for people with advanced solid tumors (commonly stomach or pancreatic cancer) who have tried at least two prior treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07675967Recruiting
Blood Cell Changes During Cancer Treatment
This study is for people with solid tumors who are about to start chemotherapy or radiation. It looks at how these treatments affect blood cells and may help doctors understand changes in blood health over time.
Boston, MassachusettsAges 18 years+
Hear when a new Gastric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric?
- Yes. Clin2 currently lists 849 recruiting gastric studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.